Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer, including providing direction for molecularly guided therapies as new indications are approved.
Transcript
How have NCCN guidelines evolved as new targeted therapies for lung cancer have been approved?
NCCN guidelines have included new indications for new agents when appropriate. That list is expanding, with recent additions including KRAS, atypical EGFR variants with the exon 20 insertion, as well as additions in MET and also considerations for agents in development and kind of awaiting results, including HER2.
The NCCN has really been important in terms of including approved guidelines across a number of different new indications for molecularly guided therapies, as well as those which are emerging. And I think that’s an important consideration. Some of the emerging molecularly guided therapies that have been listed on the NCCN guidelines include MET inhibitors for copy number gain, or increased expression, as well as for HER2—specifically for HER2 mutations compared to protein expression or copy number gain that may be important in breast cancer.
The NCCN guidelines have evolved to include the approved agents for molecularly guided approaches, as well as emerging therapies, and give understandings about the applicability of those agents, specifically under circumstances where there is high MET amplification as well as HER2 mutations.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More